Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
BrickBio develops protein and antibody-drug conjugate (ADC) therapeutics using its Evolved tRNA Localization (ETRNAL) platform, which incorporates synthetic amino acid conjugation handles at specific sites in a protein backbone via mammalian expression systems. The company targets pharmaceutical and biotech applications, aiming to produce more stable and efficacious conjugated biologics, including multi-payload conjugates.
0 investors
0 investors
Bridge Therapeutics is a development-stage pharmaceutical company developing BT-219 (Bunalz), a buprenorphine/naloxone orally disintegrating tablet for Opioid Use Disorder, and BT-205, a buprenorphine/meloxicam sublingual combination for chronic pain in opioid-experienced patients. Both drug candidates are being pursued through the FDA 505(B)(2) approval pathway.
0 investors
0 investors
0 investors
0 investors
0 investors
Bruker provides preclinical imaging solutions for research across oncology, neurology, cardiology, and other disease areas, serving academic institutions and pharmaceutical researchers.
0 investors
0 investors
Bullseye Biodevices develops a multimodal biosensing platform that combines mechanical, electrical, and optical sensing to assess tissue and organ condition in real time. The technology targets medical applications including tumor localization and surgical margin assessment, skin health monitoring, and organ evaluation during surgery, preservation, and transplantation.
0 investors
Burcon develops proprietary plant-based protein technologies for use as functional food and beverage ingredients. The company protects its novel protein extraction and processing methods through a substantial patent portfolio across multiple jurisdictions.
0 investors
Burke Therapeutics is a pharmaceutical company that markets prescription products to physicians and pharmacies across the United States and develops early-stage drug candidates for dermatological conditions with limited treatment options.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
C4 Imaging develops the SIRIUS MRI Marker, a device for precise localization of implanted LDR seeds in MRI imaging to support post-implant quality assurance in brachytherapy treatments. The product helps ensure accurate treatment delivery and protects critical anatomical structures during radiation therapy procedures.
0 investors
0 investors
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing anticoagulation and antithrombotic therapies for cardiovascular and thrombotic disorders. Its pipeline includes CAD-1005, a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia, tecarfarin for end-stage kidney disease and LVAD patients, and frunexian, an intravenous Factor XIa inhibitor for acute/critical care settings.</parameter> <parameter name="founders">[]
0 investors
0 investors
0 investors